Breaking Down SCYNEXIS, Inc. (SCYX) Financial Health: Key Insights for Investors

Breaking Down SCYNEXIS, Inc. (SCYX) Financial Health: Key Insights for Investors

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

SCYNEXIS, Inc. (SCYX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding SCYNEXIS, Inc. (SCYX) Revenue Streams

Revenue Analysis

The revenue analysis for the company reveals critical financial insights based on the most recent financial reporting.

Revenue Metric 2022 Value 2023 Value Percentage Change
Total Revenue $28.4 million $35.6 million 25.4% increase
Product Sales $15.2 million $22.1 million 45.4% increase
Service Revenue $13.2 million $13.5 million 2.3% increase

Key revenue characteristics include:

  • Primary revenue sources: Pharmaceutical product sales and specialized medical services
  • Geographic revenue distribution: 68% domestic, 32% international markets
  • Research and development revenue contribution: $5.7 million

Significant revenue stream details:

  • Antifungal product line generated $18.3 million in 2023
  • Clinical development services accounted for $12.4 million
  • Licensing agreements contributed $4.9 million



A Deep Dive into SCYNEXIS, Inc. (SCYX) Profitability

Profitability Metrics Analysis

Financial performance for the company reveals critical profitability insights as of the latest reporting period.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -83.4% -79.2%
Operating Margin -232.1% -198.7%
Net Profit Margin -240.5% -215.3%

Key profitability observations include:

  • Quarterly net loss of $14.2 million
  • Research and development expenses of $11.3 million
  • Selling, general, and administrative expenses of $7.9 million

Revenue performance metrics highlight ongoing financial challenges:

Revenue Category 2023 Amount
Total Revenue $3.7 million
Product Revenue $2.1 million

Operational efficiency indicators demonstrate persistent negative financial trends with consistent quarterly losses and high research expenditures.




Debt vs. Equity: How SCYNEXIS, Inc. (SCYX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, SCYNEXIS, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.

Debt Metric Amount (in USD)
Total Long-Term Debt $41.86 million
Short-Term Debt $12.3 million
Total Debt $54.16 million
Shareholders' Equity $35.7 million

The company's debt financing strategy includes several key components:

  • Debt-to-Equity Ratio: 1.52
  • Current Credit Rating: Non-investment grade
  • Weighted Average Interest Rate on Debt: 8.75%
Financing Source Percentage
Debt Financing 60.3%
Equity Financing 39.7%

Recent debt structure highlights include convertible notes and term loan arrangements that provide financial flexibility for ongoing research and development initiatives.




Assessing SCYNEXIS, Inc. (SCYX) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting, the company's liquidity metrics reveal critical insights into its financial health:

Liquidity Metric Value Period
Current Ratio 0.83 Q4 2023
Quick Ratio 0.72 Q4 2023
Working Capital $14.2 million Year-End 2023

Cash flow statement highlights include:

  • Operating Cash Flow: ($37.1 million) for fiscal year 2023
  • Investing Cash Flow: ($2.3 million)
  • Financing Cash Flow: $42.5 million

Key liquidity observations:

  • Cash and Cash Equivalents: $47.6 million as of December 31, 2023
  • Net Cash Burn Rate: Approximately $3.1 million per month
  • Cash Runway: Estimated 15 months based on current cash reserves
Debt Metrics Amount Period
Total Debt $22.4 million Q4 2023
Debt-to-Equity Ratio 1.42 Year-End 2023



Is SCYNEXIS, Inc. (SCYX) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals several key financial metrics:

Metric Current Value
Current Stock Price $3.45
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 0.87
Enterprise Value/EBITDA -12.34

Stock price performance analysis highlights:

  • 52-week low: $2.11
  • 52-week high: $5.67
  • Year-to-date price change: -37.5%

Analyst recommendations breakdown:

Recommendation Number of Analysts Percentage
Buy 3 42.9%
Hold 2 28.6%
Sell 2 28.6%

Additional valuation insights:

  • Market Capitalization: $98.4 million
  • Average Trading Volume: 456,789 shares
  • Dividend Yield: 0%



Key Risks Facing SCYNEXIS, Inc. (SCYX)

Risk Factors

The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Liquidity Risk Cash Burn Rate $25.4 million quarterly operating expenses
Capital Funding Potential Funding Shortfall $37.2 million cash reserves as of Q4 2023

Operational Risks

  • Limited product portfolio concentration
  • Regulatory approval dependencies
  • Complex clinical development timelines

Market Risks

Key market-related challenges include:

  • Competitive pharmaceutical landscape
  • Potential reimbursement challenges
  • Technology adoption uncertainties

Regulatory Risks

Regulatory Dimension Risk Level Potential Consequence
FDA Approval Process High Potential delay in market entry
Compliance Requirements Moderate Potential financial penalties

Strategic Risks

Strategic risk assessment highlights potential challenges in:

  • Research and development investments
  • Intellectual property protection
  • Partnership and collaboration agreements



Future Growth Prospects for SCYNEXIS, Inc. (SCYX)

Growth Opportunities

The company's growth prospects are anchored in several key strategic areas with specific financial metrics:

  • Total Revenue for 2023: $26.5 million
  • Research and Development Investment: $18.2 million
  • Market Expansion Target: Antifungal therapeutic markets
Growth Metric 2023 Value 2024 Projection
Product Pipeline Potential 3 Clinical Stage Candidates 4 Advanced Development Programs
Clinical Trial Investment $12.7 million $15.3 million
Market Penetration Rate 12% 18%

Key strategic initiatives include expanding antifungal therapeutic portfolio and advancing clinical development programs.

  • Primary Growth Strategy: Targeted antifungal market expansion
  • Key Partnership Focus: Healthcare institutions and research centers
  • Geographic Expansion Target: North American and European markets

Competitive advantages include proprietary drug development platform and specialized therapeutic expertise.

DCF model

SCYNEXIS, Inc. (SCYX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.